Mergers and acquisitions – Page 6
-
Business$2bn Immunomedics–Seattle Genetics deal delayed amid shareholder infighting
Major investor venBio seeks to derail deal and replace board members
-
BusinessReckitt Benckiser to buy into baby milk
$17bn acquisition of Mead Johnson expands presence in developing markets, especially China
-
BusinessAllergan to buy fat-freezing firm Zeltiq
$2.5bn deal adds to firm’s cosmetic and aesthetic treatments
-
BusinessSabic takes control of Shell petrochemicals joint venture
$820m sale of Saudi Arabian plants continues Shell’s global reorganisation programme
-
BusinessLilly buys CoLucid for migraine drugs
US firm also laying off 485 sales staff after Alzheimer’s drug failure
-
BusinessJ&J to buy Actelion for $30bn
Actelion’s R&D will spin out as a new company, while Janssen will take on in-market and late-stage medicines
-
Business
Novartis on winter deal spree
Swiss company aims to re-stock drug pipeline with three new deals in skin, eye and cardiovascular health
-
BusinessOpening doors to innovation
Chemical companies are increasingly using specialist investment arms to nurture new ideas
-
BusinessIpsen to buy Merrimack’s cancer drugs
$1bn deal covers two liposome-encapsulated formulations of approved therapies
-
BusinessTakeda to buy cancer specialist Ariad
Japan’s largest drug company agrees $5.2bn deal to expand oncology portfolio and boost pipeline
-
BusinessMosaic to buy Vale Fertilizantes in $2.5bn deal
Fertiliser deal continues consolidation trend and expands Mosaic’s presence in Brazil
-
BusinessLinde–Praxair merger further consolidates industrial gases
Deal will leave just three firms controlling 85% of the global market
-
BusinessMylan may lay off up to 3500 staff
The move forms part of the US generic firm’s restructuring efforts
-
-
BusinessLonza to buy capsule manufacturer in $5.5bn deal
Swiss pharma firm looks to strengthen its position as world’s biggest drug manufacturing subcontractor
-
BusinessPharmaceutical industry roundup of 2016
Controversial approvals and price clashes characterised 2016 in pharma
-
BusinessPfizer pulls back on UK and Ireland facilities
€400 million manufacturing plant expansion cancelled and two facilities to close
-
BusinessOCP to invest $3.7bn in Ethiopian fertiliser plant
Output from joint venture between Ethiopian government and Moroccan state phosphate group will exceed domestic demand
-
BusinessEU scrutinises Syngenta–ChemChina union
European commission investigates competition concerns in agricultural megamerger
-
BusinessAstraZeneca sheds multiple drugs
Spate of licensing deals for non-core products as firm further tightens R&D focus